Picture [LSA] – The Business Web Portal 650x89px
Person › Details

Michael Brandkamp (High-Tech Gründerfonds (HTGF) (Group))

Brandkamp, Michael (High-Tech Gründerfonds 201112 Managing Director)


Organisation Organisation High-Tech Gründerfonds (HTGF) (Group)
  Today High-Tech Gründerfonds Management GmbH
Products Product venture capital

High-Tech Gründerfonds Management GmbH. (12/14/11). "Press Release: BVMed, Earlybird and High-Tech Gründerfonds Launch »MedTech Radar« – a Media Service about Innovations in Medical Technology". Berlin, Bonn & Hamburg.

The German Medical Technology Association (BVMed), Earlybird Venture Capital and High-Tech Gründerfonds launch "MedTech Radar" - a joint media service about innovation transfer and financing in the medical technology sector in Germany. Illustrated with examples from the industry, the periodic media service will give an insight into the world of innovation in the medtech sector, analyse strengths and weaknesses, and provide background information. The focus of the first issue will be on innovation in the battle against heart attacks.

"The MedTech Radar is intended to provide a continual insight into new developments in the world of innovation in medical technology", says BVMed Managing Director and Board Member Joachim M. Schmitt. "We want to illustrate the important role innovation funding plays to the benefit of patients in Germany", says Dr. Michael Brandkamp, Managing Director of High-Tech Gründerfonds, describing the aim of the service. "Using examples from the industry, we will show the complex journey of a medical product - from the initial research to use by patients", explains Earlybird Partner Thom Rasche.

Germany is well established as a first-class location for developments in medical technology. As well as industry carrying out its own research and launching products, university research also supplies innovations that play an important role in medical care. However, it is a long journey for an innovation from invention to the market - and it is not always easy.

The first issue of the "MedTech Radar" explores, how a highly promising innovation that helps prevent heart attacks can be introduced to the market and why a company founder from England has come to Germany for that reason.

It is not widely known that only 15 percent of all heart attack cases result from gradual narrowing of the arteries. 85 percent are caused by a sudden rupture of inflamed fat deposits. The case study by Cryotherapeutics GmbH shows, how the targeted application of cold temperatures can be used for therapeutic purposes. The company,which is located in Potsdam, supported by High-Tech Gründerfonds, is working on the development of a -10 to -20°C catheter that will ease inflammation in the artery and prevent rupturing. "The environment in Germany in the medical technology sector is very supportive for entrepreneurs", says the English company founder Dr. John Yianni.

You can read the complete issue of MedTech Radar here
[ ]

About the publishers:

Earlybird Venture Capital is one of the most successful venture investors in Europe and currently manages over 430 million Euros of capital for an international investor base. Earlybird invests in innovative, fast-growing companies with outstanding management teams and great potential for international growth. Earlybird's portfolio currently includes more than 20 businesses in eight countries (Germany, Switzerland, Austria, Holland, UK, USA, Italy and Turkey). Since its foundation, Earlybird has invested in over 70 companies. As well as numerous successful trade sales (amaxa to Lonza, and Alantos to Amgen, among others) Earlybird has taken six portfolio companies to IPO on four different European stock exchanges (Interhyp, Tipp24 and Wilex, Esmertec, Entelos and NoemaLife). Further information is available at,, Twitter: or Facebook:

The German Medical Technology Association (BVMed) is the German Medical Technology Association. It is an industry association that represents over 230 industrial and commercial companies in the medical technology sector. Among its members are 20 of the largest medical device manufacturers worldwide in the field of consumer goods.

High-Tech Gründerfonds invests venture capital in young technology companies with good prospects that are converting promising research results into businesses. With the help of seed financing, start-up companies are able to take an R&D project to the point of producing a prototype or proof of concept, or to market launch. The fund generally invests 500,000 Euros; a total of up to two million Euros is available per company. Public-private partnership investors include the Bundesministerium für Wirtschaft und Technologie, the KfW Bankengruppe as well as the twelve industrial groups ALTANA, BASF, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Qiagen, RWE Innogy, Tengelmann and Carl Zeiss. High-Tech Gründerfonds has a total fund volume at its disposal of around 560.5 million Euros (272 million Euros in Fund I and 288.5 million Euros in Fund II).

Responsible under German press law:

BVMed - Bundesverband Medizintechnologie, Reinhardtstr. 29 b, 10117 Berlin
Manfred Beeres, Head of Communication/Press
Tel. +49 - 30 246 255-20, ,

Earlybird Venture Capital GmbH & Co KG, Van-der-Smissen-Str.3, 22767 Hamburg
Christine Höfer
Tel. +49 - 40 432941 0, ,

High-Tech Gründerfonds Management GmbH, Ludwig-Erhard-Allee 2, 53175 Bonn
Stefanie Zillikens
Tel. +49 - 228 82300107, ,

Record changed: 2019-06-09


Picture [LSA] – The Business Web Portal 650x89px

More documents for Michael Brandkamp

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top